Related Experiment Video
Updated: Mar 9, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement]
Insights
Aspirin may help prevent atherosclerotic cardiovascular disease (ASCVD) in high-risk Chinese individuals. This consensus provides guidance on aspirin use for primary and secondary ASCVD prevention, considering benefits and risks.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Atherosclerotic cardiovascular disease (ASCVD) poses a significant health burden in China.
- Aspirin is widely available and effective for ASCVD prevention, but its primary prevention role is debated.
Purpose of the Study:
- To review current evidence on aspirin use for ASCVD prevention in China.
- To provide a practical algorithm for identifying individuals who may benefit from aspirin.
- To offer recommendations on aspirin use, safety, and resistance.
Main Methods:
- Review of current evidence on aspirin for ASCVD prevention.
- Development of a risk stratification algorithm for 10-year ASCVD risk.
- Formulation of consensus recommendations for Chinese populations.
Main Results:
- Identified individuals at high 10-year ASCVD risk (≥10%) who may benefit from aspirin.
- Addressed aspirin use in primary and secondary prevention across various cardiovascular conditions.
- Highlighted safety considerations and aspirin resistance issues.
Conclusions:
- Aspirin use can be considered for primary and secondary ASCVD prevention in selected Chinese individuals.
- Risk stratification is crucial for optimizing aspirin therapy.
- Ongoing evaluation of safety and efficacy is recommended.
Abstract:
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and has the largest disease burden in China. Aspirin is the most promising agent for the prevention of ASCVD in such a large population for its easy availability and relative effectiveness, although its use in primary prevention is still a subject of debate. The joint task force has reviewed the current evidence of aspirin use in healthy population and in patients with stable coronary artery disease, acute coronary syndrome, transient ischemic attack, stroke and peripheral artery disease. The consensus statement provides a practical algorithm for identifying those at a high 10-year ASCVD risk, with more than or equal to 10%, who may benefit from aspirin use. Recommendations for aspirin use in primary and secondary prevention of ASCVD in Chinese, as well as its safety and "resistance" issues, are also stated.
